Aerospace's AI Bottleneck Is the Signature, Not the Software
AI can generate stress analysis and defect findings faster than engineers can validate them against FAA and EASA standards, and that verification capacity is the real constraint.
Find here all our blog posts tagged with: AI governance.
The Materials Discovery Boom Aerospace Regulators Can't Yet Absorb
Generative AI is outpacing aerospace certification capacity, making evidence-ready validation the real constraint on new materials programs.
Clearance or Certification: Aerospace AI's Governance Fork
Aerospace AI adoption is splitting between use-case clearance frameworks and capability-specific certification, and buyers need to know which track applies before they scale.
The Paperwork Problem Nobody's AI Has Solved
Aerospace's fragmented certification landscape is a procurement risk that ISO 42001 and EU AI Act conformity obligations are built to catch, if buyers ask.
Two Curves, One Decision: Agentic AI's Control Authority Is Outrunning Its Oversight
Industrial operators are handing agentic AI direct control authority faster than monitoring tools can verify it, and buyers need a risk tier to tell the two apart.
When the Scientist Is an Agent: Governing AI Before It Reaches the IND
Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.
When AI Agents Reach for the Controls
Anthropic's new agent-to-machine standard collapses the gap between AI recommendation and AI action, raising the stakes for industrial verification.
Design Controls Weren't Built for Models That Change
FDA is piloting exceptions rather than rewriting design controls for GenAI devices, leaving compliance leaders to build the continuous verification the rule doesn't require.
The Black Box Analogy Only Works With an NTSB Behind It
Nvidia's push for AI agent flight recorders borrows aviation's most visible artifact while skipping the investigation infrastructure that makes it useful.
Clinical Decision Support AI: Cleared, Not Proven
High-risk AI clinical decision support is scaling through FDA and IVDR pathways faster than its evidence base, leaving compliance leaders to close the gap regulators haven't.
The Plane Crash Analogy Only Works If the Toolchain Backs It Up
Tech giants want AI failures treated like aviation incidents, but that framing only holds if the underlying toolchain carries real qualification evidence.
The Sensor and the Exploit Now Share the Same Rail
A federal warning on AI-generated PLC exploits shows industrial AI's safety gains and its security exposure now sit on the same infrastructure.
Decision Assurance Has No Tail Number
Aviation's directive model regulates known parts and configurations, but AI decision-making is already being governed elsewhere, with real gaps still unresolved.
Clearance Was Never the Finish Line
FDA's predetermined change control pathway shifts the real compliance burden from initial authorization to lifecycle governance of AI models after they ship.
Cleared Is Not Validated: The Evidence Gap Behind FDA's AI Device Count
FDA's public summaries for AI-enabled devices were built to demonstrate fairness, but their format makes that fairness nearly impossible to verify.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
The Traceability Debt Building Inside AI-Native Drug Discovery
Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.
When AI Optimizes the Grid, Who Owns the Dispatch Call
AI now makes autonomous load-balancing and dispatch decisions across solar farms and virtual power plants, and no standard yet assigns liability for a bad call.
The Documentation Debt AI Drug Discovery Keeps Repeating
AI drug discovery's funding-to-approval gap echoes a governance failure regulators have already documented in medical devices, and the fix is the same.
The AI Drug Discovery Boom Is Outrunning Trial Execution
Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.
The Trial Floor Is the Next Oversight Line, Not the Device Shelf
FDA's closed RFI on AI-enabled early-phase trials signals a second oversight track distinct from device review, and sponsors are moving faster than either.
When Energy Optimization Software Becomes Grid Infrastructure
AI systems making real-time energy allocation decisions across generation, storage, and grid draw are being bought as software, not governed as infrastructure.
AI Is Entering the Maintenance Record, Not Just the Cockpit
As MRO providers adopt AI for engine maintenance decisions, the real test is whether audit trails can withstand FAA and EASA scrutiny.
The Quality Gate Aerospace Forgot to Govern
AI-driven First Article Inspection promises major efficiency gains, but aerospace manufacturers lack a governance layer to verify the verifiers.
Functional Safety Meets AI Governance on the Plant Floor
ISO/IEC TS 22440 formalizes how AI intersects with functional safety just as EU AI Act high-risk rules and ungoverned agentic deployments collide on the factory floor.
The Convergence Gap in AI Life Sciences Regulation
Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.
When AI Guides the Hands, Not Just the Read
FDA's clearance of real-time ultrasound guidance AI creates a task-shifting risk category that standard imaging AI governance does not address.
AI Defect Detection Is Outrunning the Production Certificate
Deep learning inspection is moving onto aerospace production lines faster than FAA production certificate holders can document its evidentiary basis.
FDA Is Assembling the Machinery Before It Finishes the Rule
FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.
Aviation Has a Proving Ground. It Just Doesn't Know It Yet.
A contrail trial, a maintenance rollout, and a pilot-training study show aviation already runs AI proving grounds ad hoc, with no structure connecting them.
Agentic AI Is Outrunning Machine Safety Certification
Autonomous industrial and life sciences AI is now acting inside control loops that IEC 61508, EU AI Act risk tiers, and MDR/IVDR were not built to certify.
The Evidence Gap PV Automation Never Has to Close
FDA's mounting scrutiny of AI medical devices reveals evidence gaps even for cleared products, while pharmacovigilance AI faces no such test at all.
The ISO 42001 Gap: When AI Enters the Control Loop
ISO 42001 certifies AI management systems, not real-time physical control performance, and that distinction matters as AI moves into grids, factories, and robots.
When AI Tunes the Process, Which Framework Governs the Record?
AI process control is now shaping regulated credit claims in biogas and RNG production, and no framework yet specifies who audits the machine's decision trail.
AI Is Writing Aerospace Compliance Records That Must Outlive the AI Itself
Automated AS9100 recordkeeping solves today's audit burden but creates a traceability gap when the generating system is retired before the aircraft is.
The AI Safety Layer Is Outrunning Its Own Certification
Refiners and manufacturers are embedding AI into safety-critical decisions faster than functional safety and cobot standards can validate them.
When AI Enters the Safety Loop, Deterministic Standards Start to Bend
Refiners and manufacturers are putting AI inside safety-critical decisions, but the verification standards built for deterministic control were never designed for it.
The Doctor Test for AI Devices
FDA's move toward clinician-style, ongoing assessment of AI-enabled devices reshapes what counts as durable evidence, ahead of any final guidance.
Industrial AI's Talent Pitch Assumes a Workforce It Is Depleting
The industrial AI augmentation narrative depends on a senior verification workforce that the same labor shortage driving AI adoption is actively removing.
When AI Guides the Scan, Governance Must Follow the Hands
FDA's clearance of real-time AI ultrasound guidance software shifts imaging AI governance from diagnostic accuracy to human-AI interaction validation.
Autonomous Airspace Coordination Is Outrunning Its Certification Path
NASA's Phase II award for an AI-driven airspace coordination network exposes a widening gap between deployable autonomy and the certification frameworks meant to govern it.
Airworthiness Is Becoming a Property of the System, Not the Aircraft
FAA's Part 108 drone framework and live AI forecasting in ATC decisions show certification shifting from airframes to software stacks that update faster than any type cert.
When the Algorithm Is the Biomarker
Computational pathology AI blurs device and biomarker regulation, but predetermined change control plans, not model freezing, may be the real fix.
Architecture, Not Attestation, Is the New AI Vendor Test in Energy
As grid AI moves from pilot to production, energy operators must diligence vendor architecture and control enforcement, not just policy promises.
Aviation's AI Template Has a Recognition Problem
Aviation's tiered certification model is becoming AI governance's default architecture, but its unresolved cross-border recognition gap should worry regulated AI buyers just as much.
Aviation's Assurance Gap Meets Autonomous AI
Aircraft certification and inspection regimes are built for deterministic systems, and the emerging autonomy stack is exposing what that model cannot see.
Aviation-Grade AI Governance Is Borrowing Credibility From an Unsolved Problem
Tech firms want AI incident forensics modeled on aviation, but aviation regulators admit they lack a settled method for AI safety assurance.
A Recorder Is Not an Investigator
AI vendors are borrowing aviation's black box for accountability, but the metaphor skips the investigative infrastructure that actually makes it work.
Two New Fast Lanes for AI Devices, No New Evidence Standard
EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.
The Real Bottleneck on the Floor Is the Certificate, Not the Robot
Cooperative safety certification, not AI capability, is now the gating factor for deploying humanoid robots and automation on industrial floors.
In Autonomous Flight AI, the Certification Pathway Is the Product
Regulated buyers evaluating aerospace autonomy startups should underwrite the type certificate partnership, not the model's performance claims.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
Cleared, Qualified, Authorized: Three Different Promises
Regulated buyers are treating FDA clearance, institutional platform qualification, and De Novo authorization as interchangeable seals when they carry different evidentiary weight.
The Clinical AI Governance Gap Is Structural, Not Accidental
The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.
The Clinical Trial Has No AI Rulebook
Sponsors are deploying AI across trial execution with no dedicated regulatory framework, leaving GCP and data integrity obligations to fill the gap alone.
The Compliance Evidence Layer Is Becoming Infrastructure
Open governance tooling, revised ISO 9001 rules, and national mandates are converging on one requirement: compliance evidence must be structured data, not paperwork.
The Contrail Trial Is Also an AI Act Compliance Test
Google and NATS are piloting AI contrail-avoidance forecasts inside live UK airspace, putting EU AI Act high-risk obligations to their first real operational test.
Aviation's Climate AI Needs a Verification Standard, Not Just a Model
As airlines and regulators lean on machine learning to forecast and verify contrail avoidance, the missing piece is an audit standard for the claims themselves.
The Contrail Trial Exposes a New Kind of Aviation AI Risk
A North Atlantic contrail avoidance trial shows how AI-driven environmental claims and rerouting decisions are outrunning verification and liability frameworks.
The Recorder Gap: CVR Deadlines and the Separate Question of Machine Decisions
FAA CVR upgrade deadlines fix a human-decision recording problem, but certified automation and drone autonomy are advancing on entirely separate regulatory tracks with no equivalent record.
The CVR Upgrade Deadline Is an AI Data Decision in Disguise
FAA's cockpit voice recorder mandate is a hardware deadline today, but the data architecture choices made now will determine how AI safety analytics work later.
Two Defense AI Claims, Zero Independent Verifiers, One Week
KAI's in-house UAV AI verification and Safe Pro's trade-show validation show how little civil frameworks like ISO 42001 or the EU AI Act reach into defense AI assurance.
The Missing Layer Between Airworthiness and AI Assurance
Bilateral aviation certification still works for conventional hardware, but no framework yet governs the AI and autonomous systems entering the same operational footprint.
Direct Delivery Authorization Is Colliding With AI-Driven Inspection
SAE's updated supply chain standard loosens incoming inspection just as AI-based NDT and optical inspection take over quality gates, raising a validation gap buyers must close.
Dual-Use Ambition and the Certification Fork
Whisper Aero's move toward both civil and defense markets shows why buyers must ask which certification regime an AI-enabled aircraft's assurance evidence actually targets.
EMA Moved First on AI. FDA Is Still Deciding How.
EMA's lifecycle-wide AI reflection paper and FDA's still-open genAI device rulemaking are running on different clocks, and neither is finished business for regulated buyers.
Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut
The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.
The Evidence Gap Behind AI Clinical Decision Support
AI decision support tools are scaling into hospitals faster than the evidence and oversight infrastructure needed to trust them.
FDA's Postmarket AI Machinery Is Still Under Construction
Recent FDA moves on AI-enabled devices signal a postmarket framework taking shape, but the agency's own uncertainty argues against treating early engagement as a settled strategy.
FDA's AI Perimeter Is Widening and Narrowing at the Same Time
FDA is loosening wellness device classification while tightening AI change control mechanics, and the gap between the two is where compliance risk now sits.
The Real Gap Isn't Evidence. It's Framework Fit.
AI medical device clearances are outpacing the regulatory architecture meant to govern them, and hospitals are deploying generative AI ahead of any classification at all.
FDA Clearance Is Not the Evidence Trail
FDA-authorized AI devices are outpacing the evidence behind their safety and equity claims, leaving health systems to build the diligence layer themselves.
FDA's Other AI Track: Drug Development Gets Its Own Playbook
While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.
Static Categories, Adaptive Systems: The Real Fault Line in AI Device Review
FDA and EU sandbox pilots for agentic AI are one symptom of a broader breakdown in static regulatory categories, and buyers should treat both the hype and the early-engagement tradeoffs with equal scrutiny.
The FDA Is Still Asking Questions. Brussels Already Moved Its Clock Once.
FDA's open genAI comment period and the EU's already-shifted AI Act deadlines argue for building the shared lifecycle core, not betting on either jurisdiction's paperwork.
The FDA's Open Docket Is the Real Deadline
FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.
PCCP Is Settled. The Benchmarks Underneath It Are Not.
FDA's change control pathway for AI-enabled devices is mature, but the benchmarking standards sponsors need to use it well are still unresolved.
Health AI Is Straining Categories, Not Just Rules
US data provenance, UK product classification, and Chinese jurisdictional scope are all cracking under AI health tools that don't fit pre-AI regulatory taxonomy.
FDA's New Deputy Commissioner Post Is the Real AI Signal
HHS is creating a dedicated technology leadership role at FDA, and that appointment will shape AI device oversight more than any single guidance document.
In HealthTech M&A, AI Governance Is Now a Line Item on the Term Sheet
Buyers in HealthTech and MedTech deals are pricing AI governance maturity directly into valuation, not treating it as a closing condition.
The Governance Debt Building in Drug Discovery AI
Regulatory frameworks are expanding toward AI in drug development, but the real exposure is a silent-failure risk that neither hype skeptics nor regulators are pricing in yet.
The Governance Gap Belongs to the Deployer, Not the Regulator
Hospitals and pharma functions adopting generative AI now carry governance obligations that device and drug frameworks were never built to cover.
The Governance Tooling Decision Behind Agentic AI Rollouts
A new open source coalition for AI governance testing forces energy and industrial buyers to choose between proprietary control stacks and shared standards.
Grid AI Capital Is Moving Faster Than the Proof Behind It
Energy infrastructure capital is being allocated to AI-driven grid modernization faster than utilities can document what that AI actually delivers.
When Energy AI Stops Monitoring and Starts Dispatching
AI systems are moving from monitoring power infrastructure to executing real-time control decisions, and operators lack a governance layer for who authorized that authority.
The Grid AI Decision Is a Data Custody Decision
For energy operators buying AI grid-optimization tools, the architecture choice between vendor-owned sensors and OT data access sets the cybersecurity liability line.
The Safety Case Has a Blind Spot: The Grid Behind the HAZOP Assistant
AI-augmented HAZOP validation focuses on model accuracy, but the compute and energy infrastructure the model depends on is an unaddressed safety variable.
The Icing Gap: What EASA's Admission Means for AI-Based Hazard Detection
EASA's warning that atmospheric icing remains poorly understood exposes a governance blind spot for AI systems built to detect and predict physical hazards.
The Energy Layer Missing From Industrial AI Safety Cases
AI-augmented HAZOP is testing industrial AI safety cases, but the harder unresolved question is power and grid resilience, not just compute.
The Underwriters Are Becoming the Real AI Certifiers
As aviation AI outpaces formal safety assurance, insurers are quietly setting the terms buyers must satisfy to fly.
Your ISO 27001 Certificate Does Not Cover Your AI
Same Annex SL, different risk. Why security-mature organizations have an ISO 42001 gap, what it costs in regulated industries, and why the clock is now measured in months.
ISO 42001 Gets a Precedent, Not a Verdict
NADEC's ISO 42001 certification gives industrial AI buyers a reference point, but one certificate does not settle whether the standard closes the gap between documented control and operational reality.
ISO 9001's AI Update Is a Signal, Not a Substitute
ISO 9001's revision pulls AI-influenced decisions into quality documentation, but it does not replace ISO 42001, the EU AI Act, or sector-specific AI governance.
One Journal Article Is Not Yet an AI Audit Standard
A single peer-reviewed framework is being framed as the working audit standard for generative AI mental health tools, and compliance leads should treat that framing with more caution than the coverage suggests.
Compliance Is Becoming a Data Problem, Not a Paper One
India's mandate for machine-readable product standards previews a structural shift industrial AI buyers cannot ignore: verification against static documents will not scale.
A Journal Article Is Not a Regulatory Safe Harbor
A Nature Medicine audit framework for AI mental health tools is being framed as a de facto FDA standard, but no published mechanism makes that so.
Defense AI Certification Is Becoming a Two-Track Problem
Runtime monitoring is emerging alongside, not instead of, pre-deployment certification, and buyers need to hold vendors accountable for both.
Airworthiness Doesn't End at Certification. For AI, It Can't.
A new AFWERX contract for real-time model health monitoring signals that AI assurance in defense and aerospace must be continuous, not a one-time certification event.
The PCCP Is the Real Clearance
FDA's predetermined change control plans, not the original device clearance, now define how far an AI-enabled medical device can drift without new review.
The PCCP Is the Real Decision, Not the Generative AI Docket
FDA's Predetermined Change Control Plan guidance, not the open generative AI docket, is the mechanism sponsors must decide on now for AI-enabled devices.
Physical AI Safety Is Being Priced Ahead of the Standard That Should Define It
Capital markets are pricing autonomous-machine safety infrastructure before regulators have defined what a defensible hazard dataset looks like.
Power Ahead of the Grid, Ahead of the Rules
Gigawatt-scale AI data center power deals are outrunning both utility interconnection and AI safety regulation, leaving operators to self-govern autonomous grid control.
Chip Equipment Orders Are Writing AI Governance Nobody Has Defined Yet
Samsung and SK hynix are mandating embedded AI agents in new equipment orders faster than ISO 42001 or the EU AI Act can define what compliant industrial AI actually requires.
Static Certification, Shifting Models: What's Actually New
The gap between one-time AI certification and continuous model drift is old news; the funding and liability questions forming around it are not.
The Next Safety Case Needs a New Kind of Evidence
Explainability and adversarial robustness are becoming safety-case requirements, and aerospace buyers should demand that evidence before regulators mandate it.
Shared AI Safety Tools, No Accountable Owner
A joint runway incursion initiative and AI-driven safety reporting tools push AI into cross-organizational safety decisions without a clear accountability structure.
AI Threat Detection Is Moving to Orbit Faster Than Assurance Can Follow
Space operators are adopting AI-enabled threat detection and zero-trust architectures with no sector-specific certification regime to verify the claims.
The Rulebook Is Being Written While the Machines Run
International standards bodies are drafting industrial AI rules in real time, forcing compliance leaders to build on existing frameworks rather than wait for finished ones.
Two Risk Ledgers, One Autonomous Agent
Industrial AI autonomy and AI agent security are the same governance question asked from opposite ends, and only one side has drawn real investment.
The Grid Is Becoming a Control Loop, But the Case Isn't Closed
AI is moving from grid advisory to grid execution, but the pace is a bet on scaling, not a settled fact, and assurance regimes haven't caught up either way.
What You Didn't Automate Is Now a Governance Artifact
As industrial AI deployment accelerates unevenly, the decision to withhold automation is becoming as auditable as the decision to deploy it.
The Watching Layer Gets Regulated Too
As AI-based safety monitoring scales across industrial sites, the surveillance systems themselves are becoming a governance and cybersecurity liability, not just a sensor purchase.
Aviation's Assurance Gap Is Two Problems, Not One
Aviation safety leaders are being sold a single fix for what are actually two distinct AI assurance failures, and conflating them will leave both unaddressed.
The Governance Gap in Clinical Trial Operations AI
Agentic AI is spreading through trial enrollment, monitoring, and feasibility work faster than FDA, EU AI Act, or ISO 42001 pathways built for medical devices can reach it.
The Vendor Concentration Risk Utilities Aren't Pricing In
As utilities wire agentic AI platforms into grid operations to capture real savings, few have updated vendor governance for critical infrastructure dependency.
Vertical AI's Pitch Meets a Regulatory Reality Check
A sponsored case for vertical AI in utilities collides with a real state-level regulatory split, and the fix is narrower than a single governance framework.
The Verification Problem Is Migrating From Policy to Protocol
As Anthropic formalizes how AI agents talk to machines, industrial verification is shifting from governance policy to interface protocol before regulators arrive.
Industrial AI's Real Bottleneck Is Who Signs Off On It
As industrial AI vendors race to automate control logic and physical machine operation, regulated operators still lack a named answer to who verifies the output.
One Algorithm, Two Rulebooks: The Wearable AI Compliance Gap
FDA's looser wellness classification for AI wearables collides with the EU AI Act's stricter high-risk tiering, forcing global device makers to design for the harder standard first.
Who Owns the Compliance Layer When Vendors Acquire It
Dassault's purchase of ArisGlobal and Red Hat's open agent-safety project show two competing paths for AI governance, and industrial buyers must pick one before they scale agentic AI.
